CoChat

Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy

Open access
Ahmadzadehfar, Hojjat, Schlolaut, Stephan, Fimmers, Rolf, Yordanova, Anna, Hirzebruch, Stefan, Schlenkhoff, Carl, Gaertner, Florian C., Awang, Zool Hilmi, Hauser, Stefan, Essler, Markus · 2017 · Oncotarget
Cited by 86

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

// Hojjat Ahmadzadehfar 1, * , Stephan Schlolaut 1, * , Rolf Fimmers 2 , Anna Yordanova 1 , Stefan Hirzebruch 1 , Carl Schlenkhoff 1 , Florian C. Gaertner 1 , Zool Hilmi Awang 1 , Stefan Hauser 3 and Markus Essler 1 1 Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany 2 Institute for Medical Biometry, Informatics and Epidemiology, University of Bonn, Germany 3 Department of Urology, University Hospital Bonn, Bonn, Germany * These authors contributed equally to this work Correspondence to: Hojjat Ahmadzadehfar, email: hojjat.ahmadzadehfar@ukb.uni-bonn.de Keywords: 177 Lu, overall survival, PSMA, radioligand therapy, prostate cancer Received: August 25, 2017 Accepted: October 04, 2017 Published: October 07, 2017 ABSTRACT Prostate-specific membrane antigen (PSMA) is a promising target for the diagnosis of and therapy for metastatic castration-resistant prostate cancer (mCRPC). The aim of this study was to measure overall-survival (OS) in mCRPC patients who received either abiraterone or enzalutamide prior to PSMA therapy. The second aim of this study was to analyse the predictors of OS according to different pre-therapeutic parameters and also the responses to the first cycle of radioligand therapy (RLT) base on PSA level. Patients with mCRPC and a history of therapy with either abiraterone or enzalutamide or both, were included in this study. Different laboratory tests and pre-therapeutic parameters have been included into the analysis. One-hundred patients received a total of 347 cycles of Lu-PSMA (median: three cycles). 69 patients showed a decline in PSA two months after the first cycle, and 38 of those patients showed a PSA decline of = > 50%. The median OS was 60 weeks. In the multivariate analysis, the level of albumin, AST and haemoglobin, existence of liver metastases and a decline of > 14% in PSA level had a significant impact on overall-survival. The median OS is significantly longer in patients without hepatic involvement, with high levels of albumin and Hb and low levels of AST. A decline in PSA levels of more than 14% was the most important response parameter with regard to overall survival.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.21600

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 86

Metadata

Authors
Ahmadzadehfar, H., Schlolaut, S., Fimmers, R., Yordanova, A., Hirzebruch, S., Schlenkhoff, C., Gaertner, F. C., Awang, Z. H., Hauser, S., & Essler, M.
Venue
Oncotarget
Published
2017-10-07
Volume
8
Issue
61
Pages
103108-103116
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2763185726
Cited by
86
References
3
FWCI
6.63
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy. https://app.cochat.ai/papers/10.18632/oncotarget.21600
The paper
Ahmadzadehfar, H., Schlolaut, S., Fimmers, R., Yordanova, A., Hirzebruch, S., Schlenkhoff, C., Gaertner, F. C., Awang, Z. H., Hauser, S., & Essler, M. (2017). Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy. Oncotarget. https://doi.org/10.18632/oncotarget.21600

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.